# DKSH entered a strategic distribution partnership with BridgeBio

- Link: https://www.thailand-business-news.com/pr-news/dksh-entered-a-strategic-distribution-partnership-with-bridgebio
- Published: 2026-06-11T12:50:00+07:00
- Author: Media OutReach

#### _DKSH entered a strategic distribution partnership with BridgeBio to support regulatory evaluation and potential patient access to a Transthyretin Stabilizer for ATTR-CM in Australia, Singapore, South Korea, and Taiwan. The partnership combines BridgeBio’s biotech innovation and DKSH Healthcare’s integrated end-to-end commercialization platform to bring a new treatment option to patients._

SINGAPORE – EQS Newswire – 11 June 2026 – DKSH Business Unit Healthcare, a strategic
healthcare business partner and leading provider of Market Expansion Services for
pharmaceutical, over-the-counter (OTC), consumer health and medical device companies,
has entered a distribution partnership with BridgeBio, a biotechnology company focused
on genetic diseases. Under the terms of the agreement, DKSH will be responsible 
for the distribution and commercialization of the transthyretin stabilizer for ATTR-
CM across Australia, Singapore, South Korea, and Taiwan.

 Where approved, the product is indicated for the treatment of the cardiomyopathy
of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to
reduce cardiovascular death and cardiovascular-related hospitalization^(1). ATTR-
CM is a progressive, debilitating disease that diminishes quality of life, causes
recurrent hospitalizations, and leads to premature death. This new treatment is 
not currently approved in the countries covered by this agreement and any commercialization
will be subject to applicable regulatory approvals and local regulations.

 DKSH will provide end-to-end solutions prioritizing healthcare access to patients,
leveraging its expertise in regulatory affairs, medical affairs, market access, 
and launch excellence, as well as its robust distribution infrastructure and integrated
commercial capabilities. DKSH is well positioned to support the introduction of 
this biotech innovation across the Territory following regulatory approvals.^(2 
3 4)

 “Our strategic partnership with BridgeBio represents an important milestone as 
DKSH Healthcare enters a new chapter with a renewed vision for growth. United by
a shared commitment to improve outcomes for underserved patients, we are proud to
combine BridgeBio’s scientific innovation with DKSH Healthcare’s industry‑leading,
end‑to‑end commercialization platform. Leveraging our deep market expertise, strong
capabilities, and trusted execution across complex healthcare systems, we are well
positioned to launch this biotech innovation and expand access to important new 
treatment options reliably, responsibly, and at scale, advancing on our mission 
to deliver Healthcare for All,” said Patrik Grande, Global Head of Business Unit
Healthcare, DKSH.

 ^(1 )FDA, Full Prescribing Information. Available at: 
 https://www.accessdata.
fda.gov/drugsatfda_docs/label/2024/216540s000lbl.pdf Last accessed March 2026.  
^(2) Lane T, et al. Circulation. 2019;140(1):16-26.  ^(3) Rintell D, et al. Orphanet
J Rare Dis. 2021;16(1):70.  ^(4) Nativi-Nicolau J, et al. ESC Heart Fail. 2021;8(
5):3875-3884Hashtag: #DKSH

The issuer is solely responsible for the content of this announcement.

#### About DKSH

For more than 160 years, DKSH has been delivering growth for companies in Asia Pacific,
Europe, and North America across its Business Units Healthcare, Consumer Goods, 
Performance Materials, and Technology. As a leading Market Expansion Services provider,
DKSH offers sourcing, market insights, marketing and sales, e-commerce, distribution
and logistics as well as after-sales services, following its purpose of enriching
people’s lives. DKSH is a participant of the United Nations Global Compact and adheres
to its principles-based approach to responsible business. Listed on the SIX Swiss
Exchange, DKSH operates in 35 markets with 26,840 specialists, generating net sales
of CHF 11.1 billion in 2025. DKSH Business Unit Healthcare distributes pharmaceuticals,
consumer health, over-the-counter products and medical devices. With around 7,580
specialists, the Business Unit generated net sales of CHF 5.8 billion in 2025. [www.dksh.com/hec](http://www.dksh.com/hec)

![](//track.media-outreach.com/index.php/WebView/469996/36955)

**Source** : [DKSH entered a strategic distribution partnership with BridgeBio](https://www.media-outreach.com/news/singapore/2026/06/11/469996/?rand=186006)

---

  |  This article was produced by Media OutReach, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not reflect the opinions of Thailand Business News. |

---

![Media OutReach Newswire](https://i0.wp.com/www.thailand-business-news.com/wp-content/
uploads/2025/04/media-outreach-20025.png?ssl=1)
